Meeting
2020 ASCO Virtual Scientific Program
Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.
Authors
John C. Byrd
The Ohio State University Comprehensive Cancer Center, Columbus, OH
John C. Byrd , Jennifer Ann Woyach , Richard R. Furman , Peter Martin , Susan Mary O'Brien , Jennifer R. Brown , Deborah Marie Stephens , Jacqueline Claudia Barrientos , Stephen Devereux , Peter Hillmen , John M. Pagel , Ahmed M. Hamdy , Raquel Izumi , Priti Patel , Min Hui Wang , Nitin Jain , William G. Wierda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02029443
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8024)
DOI
10.1200/JCO.2020.38.15_suppl.8024
Abstract #
8024
Poster Bd #
357
Abstract Disclosures
Similar Posters
First Author: Tycel Jovelle Phillips
Poster
2022 ASCO Annual Meeting
Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
First Author: L Elizabeth Budde
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2021 ASCO Annual Meeting
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.
First Author: Jeff Porter Sharman